Arcturus Therapeutics

Arcturus Therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics

/wp-content/themes/rewalk-parent/default_media/arcturus_space_1mbit_vbr2.mp4
News & Events
March 4, 2013
Arcturus Therapeutics Begins Operations in Janssen Labs
READ MORE
May 8, 2013
Arcturus Therapeutics Announces New Appointments to its Board of Directors and Scientific Advisory Board
READ MORE
June 1, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 3, 2013
With $1.3M in Seed Funding, Arcturus Adds to RNAi Hub in San Diego
READ MORE
June 3, 2013
RNAi therapeutics startup sets up shop at Janssen labs, closes $1.3M seed round
READ MORE
June 3, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 4, 2013
Janssen Labs-based Arcturus gets $1.3M boost for RNAi delivery tech
READ MORE
June 4, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 4, 2013
Startup Arcturus Pulls in $1.3M in Seed Money amid Renewed Interest in RNAi
READ MORE
August 14, 2013
Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech
READ MORE
August 14, 2013
Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina
READ MORE
August 15, 2013
San Diego upstart acquires RNA tech from cash-strapped Marina Biotech
READ MORE
August 15, 2013
San Diego Life Sciences Roundup: Vical, Fate, Arcturus, and More
READ MORE
August 15, 2013
Arcturus Therapeutics Acquires Patent Portfolio from Marina Biotech
READ MORE
August 15, 2013
Marina Sells UNA Patent Estate to Arcturus as It Looks to Resume Operations
READ MORE
October 21, 2013
GenomeWeb Acturus Closes $5M Series A Round, Aims for Clinic in '15 with RNAi Drug
READ MORE
October 21, 2013
RNAi firm raises $5M to develop and deliver drugs that turn off disease-causing genes
READ MORE
October 21, 2013
Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
READ MORE
October 12, 2021
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
READ MORE
October 20, 2021
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
October 21, 2021
Arcturus Therapeutics Announces Leadership Appointments
READ MORE
October 25, 2021
Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021
READ MORE
November 8, 2021
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
READ MORE
November 18, 2021
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
November 22, 2021
Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
READ MORE
December 13, 2021
Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors
READ MORE
December 16, 2021
Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
READ MORE
January 24, 2022
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
READ MORE
January 25, 2022
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
READ MORE
February 8, 2022
Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
READ MORE
February 16, 2022
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
READ MORE
February 28, 2022
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress
READ MORE
March 25, 2022
Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
READ MORE
April 20, 2022
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
READ MORE
April 27, 2022
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022
READ MORE
May 5, 2022
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
READ MORE
May 9, 2022
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
READ MORE
August 1, 2022
Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022
READ MORE
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/Arcturus_Lobby_Large.jpg?time=1659943196
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/Arcturus_Lobby_Small.jpg?time=1659943196
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2022/07/22ArctP750_crop-scaled.jpg?time=1659943196
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2022/07/22ArctP750_crop-scaled.jpg?time=1659943196
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/05/18arct1244fxF.jpg?time=1659943196
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/05/18arct1244fxF_230.jpg?time=1659943196
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/ArcBuilding_Final.jpg?time=1659943196
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/building_external_thumbnail.jpg?time=1659943196
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/05/18arct1055fxF.jpg?time=1659943196
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/05/18arct1055fxF_230.jpg?time=1659943196
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2016/05/main-visual-office-exterior.jpg?time=1659943196
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/main_office_exterior_thumbnail.jpg?time=1659943196
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2016/05/main-visual-office-interior-tag-line.jpg?time=1659943196
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/building_tagline_thumbnail.jpg?time=1659943196
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/09/20arctlab286fxFNLLo-scaled.jpg?time=1659943196
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/20arctlab286fxFNLLo_thumbnail.jpg?time=1659943196
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/09/20arctlab206fxFNLLo-scaled.jpg?time=1659943196
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/20arctlab206fxFNLLo_thumbnail.jpg?time=1659943196

LUNAR®-mediated delivery of RNA into cells

LUNAR® particles associate with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis.

Upon entering the cytosol, the LUNAR® formulations then become trapped in the endosomes.

With increased acidity as the endosome ages, a pH-mediated disruption enables release of the RNA payload following rapid biodegradation of the LUNAR®components.

Once release of the RNA into the cytosol occurs, the translational machinery can interact with the RNA and processing and/or trafficking can then take place to make functional protein.

LUNAR® lipid mediated delivery enables delivery of RNA medicines.